Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMED Globus Medical	$57.09 -1.2%	$60.18	$54.48 ▼ $94.93	$7.82B	1.19	1.16 million shs	1.41 million shs
HAE Haemonetics	$75.55 -3.4%	$70.50	$55.30 ▼ $94.99	$3.76B	0.39	675,269 shs	660,605 shs
HRC Hill-Rom	$155.96	$155.74	$93.34 ▼ $156.22	$10.30B	0.55	656,912 shs	N/A
IRTC iRhythm Technologies	$135.94 +0.9%	$142.96	$55.92 ▼ $157.13	$4.30B	1.41	489,235 shs	562,298 shs
NVRO Nevro	$5.85 +0.1%	$5.85	$3.17 ▼ $10.37	$224.32M	0.81	802,529 shs	753,602 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMED Globus Medical	+0.86%	-2.27%	-5.91%	-20.61%	-16.83%
HAE Haemonetics	+0.72%	+1.96%	+8.56%	+30.66%	-10.00%
HRC Hill-Rom	0.00%	0.00%	0.00%	0.00%	0.00%
IRTC iRhythm Technologies	+1.38%	-5.38%	-9.30%	+31.95%	+42.10%
NVRO Nevro	0.00%	0.00%	0.00%	0.00%	-27.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMED Globus Medical	4.9406 of 5 stars	4.3	5.0	0.0	4.1	2.0	2.5	1.9
HAE Haemonetics	4.9075 of 5 stars	4.5	2.0	0.0	4.3	2.8	1.7	2.5
HRC Hill-Rom	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	1.2579 of 5 stars	2.5	1.0	0.0	0.0	2.7	0.8	0.6
NVRO Nevro	0.1933 of 5 stars	1.0	0.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMED Globus Medical	2.62	Moderate Buy	$94.00	64.65% Upside
HAE Haemonetics	3.00	Buy	$97.30	28.79% Upside
HRC Hill-Rom	0.00	N/A	N/A	N/A
IRTC iRhythm Technologies	2.90	Moderate Buy	$138.60	1.96% Upside
NVRO Nevro	1.92	Reduce	$5.36	-8.29% Downside

Current Analyst Ratings Breakdown

Latest HRC, GMED, HAE, IRTC, and NVRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	HAE Haemonetics	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$95.00
7/9/2025	HAE Haemonetics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00
6/26/2025	HAE Haemonetics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/25/2025	HAE Haemonetics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/11/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $160.00
6/10/2025	GMED Globus Medical	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/27/2025	GMED Globus Medical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/27/2025	GMED Globus Medical	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/22/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $167.00
5/20/2025	HAE Haemonetics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$100.00 ➝ $100.00
5/12/2025	GMED Globus Medical	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$80.00 ➝ $68.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMED Globus Medical	$2.52B	3.07	$6.58 per share	8.68	$30.40 per share	1.88
HAE Haemonetics	$1.36B	2.67	$6.96 per share	10.85	$16.34 per share	4.62
HRC Hill-Rom	$3.02B	3.41	$9.29 per share	16.79	$28.56 per share	5.46
IRTC iRhythm Technologies	$591.84M	7.33	N/A	N/A	$2.90 per share	46.88
NVRO Nevro	$408.52M	0.55	N/A	N/A	$8.10 per share	0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMED Globus Medical	$102.98M	$1.34	42.60	14.17	1.68	7.39%	10.52%	8.56%	8/5/2025 (Estimated)
HAE Haemonetics	$167.68M	$3.31	22.82	14.99	1.27	12.32%	26.37%	9.22%	8/14/2025 (Estimated)
HRC Hill-Rom	$248.50M	$3.72	41.92	21.72	N/A	8.23%	23.07%	8.96%	N/A
IRTC iRhythm Technologies	-$113.29M	-$3.14	N/A	N/A	N/A	-15.90%	-101.04%	-9.55%	7/30/2025 (Estimated)
NVRO Nevro	-$92.21M	-$3.05	N/A	N/A	N/A	-16.54%	-23.52%	-10.83%	8/4/2025 (Estimated)

Latest HRC, GMED, HAE, IRTC, and NVRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IRTC iRhythm Technologies	-$0.53	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	GMED Globus Medical	$0.79	N/A	N/A	N/A	$738.91 million	N/A
5/8/2025	Q1 2025	GMED Globus Medical	$0.74	$0.68	-$0.06	$0.54	$629.74 million	$598.12 million
5/8/2025	Q4 2025	HAE Haemonetics	$1.22	$1.24	+$0.02	$1.17	$329.38 million	$330.60 million
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMED Globus Medical	N/A	N/A	N/A	N/A	N/A
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
HRC Hill-Rom	$0.96	0.62%	N/A	25.81%	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
NVRO Nevro	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMED Globus Medical	N/A	4.45	2.72
HAE Haemonetics	1.12	1.62	0.99
HRC Hill-Rom	0.97	1.38	1.05
IRTC iRhythm Technologies	7.47	5.71	5.58
NVRO Nevro	0.67	5.02	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMED Globus Medical	95.16%
HAE Haemonetics	99.67%
HRC Hill-Rom	76.45%
IRTC iRhythm Technologies	N/A
NVRO Nevro	95.52%

Insider Ownership

Company	Insider Ownership
GMED Globus Medical	18.51%
HAE Haemonetics	1.84%
HRC Hill-Rom	0.69%
IRTC iRhythm Technologies	1.10%
NVRO Nevro	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMED Globus Medical	5,300	135.38 million	110.32 million	Optionable
HAE Haemonetics	3,023	48.04 million	47.16 million	Optionable
HRC Hill-Rom	10,000	66.05 million	65.59 million	Optionable
IRTC iRhythm Technologies	2,000	31.92 million	31.57 million	Optionable
NVRO Nevro	1,090	38.37 million	36.27 million	Optionable

HRC, GMED, HAE, IRTC, and NVRO Headlines

Recent News About These Companies

Nevro Corp. (NYSE:NVRO) Receives Average Rating of "Reduce" from Analysts

July 6, 2025 | americanbankingnews.com

Zimmer hires former Nevro CEO Kevin Thornal

May 27, 2025 | medtechdive.comM

Nevro Corp. Data Breach - Levi & Korsinsky, LLP Launches Investigation

April 22, 2025 | accessnewswire.comA

INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach

April 21, 2025 | accessnewswire.comA

Nevro Corp. Data Breach under Investigation by Levi & Korsinsky, LLP

April 21, 2025 | accessnewswire.comA

Nevro Corp. Data Breach - Levi & Korsinsky, LLP Launches Investigation

April 18, 2025 | accessnewswire.comA

Nevro Corp. Data Breach - Levi & Korsinsky, LLP Launches Investigation

April 17, 2025 | accessnewswire.comA

Nevro Corp. Data Breach Under Investigation by Levi & Korsinsky, LLP

April 16, 2025 | accessnewswire.comA

INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach

April 15, 2025 | accessnewswire.comA

Levi & Korsinsky, LLP Investigates Nevro Corp. Data Breach

April 14, 2025 | accessnewswire.comA

Levi & Korsinsky, LLP Investigates Nevro Corp. Data Breach

April 14, 2025 | accessnewswire.comA

INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach

April 11, 2025 | accessnewswire.comA

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Nevro Corp. Customers Whose Data May Have Been Compromised

April 10, 2025 | globenewswire.com

INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach

April 10, 2025 | accessnewswire.comA

Nevro Corp. Data Breach - Levi & Korsinsky, LLP Launches Investigation

April 9, 2025 | accessnewswire.comA

INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data Breach

April 8, 2025 | accessnewswire.comA

Nevro Files Notice of Data Breach Affecting Confidential Consumer Information

April 5, 2025 | jdsupra.com

Nevro Corp. Investigated by Federman & Sherwood for Data Breach

April 3, 2025 | globenewswire.com

Why Is Nevro (NVRO) Up 0.9% Since Last Earnings Report?

April 3, 2025 | zacks.com

Globus Medical Completes Acquisition of Nevro Corp.

April 3, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRC, GMED, HAE, IRTC, and NVRO Company Descriptions

Globus Medical NYSE:GMED

$57.09 -0.71 (-1.23%)

Closing price 03:59 PM Eastern

Extended Trading

$57.10 +0.00 (+0.01%)

As of 04:10 PM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Haemonetics NYSE:HAE

$75.55 -2.62 (-3.35%)

Closing price 03:59 PM Eastern

Extended Trading

$74.70 -0.85 (-1.13%)

As of 05:50 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Hill-Rom NYSE:HRC

Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.

iRhythm Technologies NASDAQ:IRTC

$135.94 +1.23 (+0.91%)

Closing price 04:00 PM Eastern

Extended Trading

$135.56 -0.38 (-0.28%)

As of 04:20 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)

Closing price 04/2/2025

Extended Trading

$5.85 0.00 (0.00%)

As of 04/2/2025 07:56 PM Eastern

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time